PURPOSE: To determine the difference in gene expression between completely versus incompletely enhancing glioblastoma multiforme (GBM). MATERIALS AND METHODS: Gene expression was determined for 52 newly diagnosed GBMs by using DNA microarrays, and the relationship to enhancement pattern and survival was analyzed. This study was approved by the institutional review board and was HIPAA compliant; informed consent was obtained. RESULTS: Thirty-eight percent (20 of 52) of GBMs were incompletely enhancing (IE). The expression of eight genes was increased more than twofold in IE GBM when compared with completely enhancing (CE) GBM. Among these were tight junction protein-2 (2.2-fold increase, P = .019), and the oligodendroglioma markers oligodendrocyte lineage transcription factor 2 (2.4-fold increase, P = .029) and Achaete-scute complex-like 1 (ASCL1; 2.7-fold increase, P = .023). The expression of 71 genes showed relative overexpression in CE when compared with IE GBM. These included several proangiogenic and edema-related genes, including vascular endothelial growth factor (2.1-fold, P = .005) and neuronal pentraxin-2 (3.0-fold, P = .029). Several genes associated with primary GBM were overexpressed in CE tumors, whereas ASCL1, which is associated with secondary GBM, was overexpressed in IE tumors. Many genes overexpressed in IE GBM were associated with longer survival, whereas several genes overexpressed in CE GBM correlated with shortened survival. CONCLUSION: The enhancement pattern divides GBM in two groups with differing prognoses. By comparing gene expression between IE and CE GBMs, it was possible to identify genes that may affect magnetic resonance imaging features of edema and enhancement, and genes whose expression levels are predictive of both improved and shortened survival. (c) RSNA, 2008.
PURPOSE: To determine the difference in gene expression between completely versus incompletely enhancing glioblastoma multiforme (GBM). MATERIALS AND METHODS: Gene expression was determined for 52 newly diagnosed GBMs by using DNA microarrays, and the relationship to enhancement pattern and survival was analyzed. This study was approved by the institutional review board and was HIPAA compliant; informed consent was obtained. RESULTS: Thirty-eight percent (20 of 52) of GBMs were incompletely enhancing (IE). The expression of eight genes was increased more than twofold in IE GBM when compared with completely enhancing (CE) GBM. Among these were tight junction protein-2 (2.2-fold increase, P = .019), and the oligodendroglioma markers oligodendrocyte lineage transcription factor 2 (2.4-fold increase, P = .029) and Achaete-scute complex-like 1 (ASCL1; 2.7-fold increase, P = .023). The expression of 71 genes showed relative overexpression in CE when compared with IE GBM. These included several proangiogenic and edema-related genes, including vascular endothelial growth factor (2.1-fold, P = .005) and neuronal pentraxin-2 (3.0-fold, P = .029). Several genes associated with primary GBM were overexpressed in CE tumors, whereas ASCL1, which is associated with secondary GBM, was overexpressed in IE tumors. Many genes overexpressed in IE GBM were associated with longer survival, whereas several genes overexpressed in CE GBM correlated with shortened survival. CONCLUSION: The enhancement pattern divides GBM in two groups with differing prognoses. By comparing gene expression between IE and CE GBMs, it was possible to identify genes that may affect magnetic resonance imaging features of edema and enhancement, and genes whose expression levels are predictive of both improved and shortened survival. (c) RSNA, 2008.
Authors: Ruty Shai; Tao Shi; Thomas J Kremen; Steve Horvath; Linda M Liau; Timothy F Cloughesy; Paul S Mischel; Stanley F Nelson Journal: Oncogene Date: 2003-07-31 Impact factor: 9.867
Authors: William A Freije; F Edmundo Castro-Vargas; Zixing Fang; Steve Horvath; Timothy Cloughesy; Linda M Liau; Paul S Mischel; Stanley F Nelson Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: H Nakamura; Y Fujii; I Inoki; K Sugimoto; K Tanzawa; H Matsuki; R Miura; Y Yamaguchi; Y Okada Journal: J Biol Chem Date: 2000-12-08 Impact factor: 5.157
Authors: Aaron A Cohen-Gadol; Michael L DiLuna; Sergei I Bannykh; Joseph M Piepmeier; Dennis D Spencer Journal: Neurosurg Rev Date: 2004-07-28 Impact factor: 3.042
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: Alireza Biglari; Dominique Bataille; Ulrike Naumann; Michael Weller; Jeffrey Zirger; Maria G Castro; Pedro R Lowenstein Journal: Cancer Gene Ther Date: 2004-11 Impact factor: 5.987
Authors: Susan K Hobbs; Gongyi Shi; Ron Homer; Griff Harsh; Scott W Atlas; Mark D Bednarski Journal: J Magn Reson Imaging Date: 2003-11 Impact factor: 4.813
Authors: A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen Journal: Neurology Date: 2008-03-04 Impact factor: 9.910
Authors: Chih-Chun Wu; Rajan Jain; Lucidio Neto; Seema Patel; Laila M Poisson; Jonathan Serrano; Victor Ng; Sohil H Patel; Dimitris G Placantonakis; David Zagzag; John Golfinos; Andrew S Chi; Matija Snuderl Journal: Neuroradiology Date: 2019-05-27 Impact factor: 2.804
Authors: Elke Hattingen; Alina Jurcoane; Keivan Daneshvar; Ulrich Pilatus; Michel Mittelbronn; Joachim P Steinbach; Oliver Bähr Journal: Neuro Oncol Date: 2013-08-07 Impact factor: 12.300
Authors: R Jain; L Poisson; J Narang; L Scarpace; M L Rosenblum; S Rempel; T Mikkelsen Journal: AJNR Am J Neuroradiol Date: 2012-03-15 Impact factor: 3.825
Authors: Michael DeLay; Arman Jahangiri; W Shawn Carbonell; Yu-Long Hu; Sean Tsao; Maxwell Wing Tom; Jesse Paquette; Taku A Tokuyasu; Manish K Aghi Journal: Clin Cancer Res Date: 2012-04-03 Impact factor: 12.531
Authors: W B Pope; L Mirsadraei; A Lai; A Eskin; J Qiao; H J Kim; B Ellingson; P L Nghiemphu; S Kharbanda; R H Soriano; S F Nelson; W Yong; H S Phillips; T F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2012-01-19 Impact factor: 3.825
Authors: Rajan Jain; Derek R Johnson; Sohil H Patel; Mauricio Castillo; Marion Smits; Martin J van den Bent; Andrew S Chi; Daniel P Cahill Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Kourosh M Naeini; Whitney B Pope; Timothy F Cloughesy; Robert J Harris; Albert Lai; Ascia Eskin; Reshmi Chowdhury; Heidi S Phillips; Phioanh L Nghiemphu; Yalda Behbahanian; Benjamin M Ellingson Journal: Neuro Oncol Date: 2013-02-26 Impact factor: 12.300
Authors: Melanie Kappadakunnel; Ascia Eskin; Jun Dong; Stanley F Nelson; Paul S Mischel; Linda M Liau; Phioanh Ngheimphu; Albert Lai; Timothy F Cloughesy; Jonathan Goldin; Whitney B Pope Journal: J Neurooncol Date: 2009-08-05 Impact factor: 4.130